Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 20523864)

1.

Recent advances in pharmacotherapy of atrial fibrillation.

Singh J, Braich JS.

Indian J Pharmacol. 2009 Aug;41(4):153-7. doi: 10.4103/0253-7613.56064.

3.

Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.

Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J.

Am J Cardiol. 2003 Mar 20;91(6A):15D-26D. Review.

PMID:
12670638
4.

Novel approaches for pharmacological management of atrial fibrillation.

Ehrlich JR, Nattel S.

Drugs. 2009;69(7):757-74. doi: 10.2165/00003495-200969070-00001. Review.

PMID:
19441867
5.
6.

Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.

Li D, Sun H, Levesque P.

Cardiovasc Hematol Agents Med Chem. 2009 Jan;7(1):64-75. Review.

PMID:
19149545
7.

New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.

Nattel S, Khairy P, Roy D, Thibault B, Guerra P, Talajic M, Dubuc M.

Drugs. 2002;62(16):2377-97. Review.

PMID:
12396229
8.

Do we need pharmacological therapy for atrial fibrillation in the ablation era?

Lévy S.

J Interv Card Electrophysiol. 2006 Dec;17(3):189-94. Epub 2007 Mar 6. Review.

PMID:
17340189
9.

Pharmacological approaches in the treatment of atrial fibrillation.

Tamargo J, Caballero R, Delpón E.

Curr Med Chem. 2004 Jan;11(1):13-28. Review.

PMID:
14754423
10.

Cardioversion for atrial fibrillation: treatment options and advances.

Reiffel JA.

Pacing Clin Electrophysiol. 2009 Aug;32(8):1073-84. doi: 10.1111/j.1540-8159.2009.02441.x. Review.

PMID:
19659629
11.

Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation.

Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, Pepper C, Todd D, Woolacott N.

Health Technol Assess. 2008 Nov;12(34):iii-iv, xi-xiii, 1-198. Review.

12.
13.

Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.

Singh BN, Mody FV, Lopez B, Sarma JS.

Am J Cardiol. 1999 Nov 4;84(9A):161R-173R. Review.

PMID:
10568677
14.

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.

Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ.

J Am Coll Cardiol. 2005 Jun 7;45(11):1832-9.

15.

Non-antiarrhythmic drugs to prevent atrial fibrillation.

Moro C, Hernández-Madrid A, Matía R.

Am J Cardiovasc Drugs. 2010;10(3):165-73. doi: 10.2165/11537270-000000000-00000. Review.

PMID:
20524718
16.

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation.

Zheng B, Kang J, Tian Y, Tang R, Long D, Yu R, He H, Zhang M, Shi L, Tao H, Liu X, Dong J, Ma C.

Acta Cardiol. 2009 Jun;64(3):335-40.

PMID:
19593943
17.

Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits.

Camm J.

Int J Cardiol. 2012 Mar 22;155(3):362-71. doi: 10.1016/j.ijcard.2011.06.012. Review.

PMID:
21708411
18.
19.
20.

Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial.

Madrid AH, Escobar C, Rebollo JM, Marín I, Bernal E, Nannini S, Limón L, Peng J, Moro C.

Card Electrophysiol Rev. 2003 Sep;7(3):243-6. Review.

PMID:
14739722
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk